A polymer nanoparticle with engineered affinity for a vascular endothelial growth factor (VEGF₁₆₅)

Area of Science:

• Biotechnology
• Materials Science
• Molecular Biology

Background:

• Protein affinity reagents, primarily antibodies, are crucial in research, diagnostics, and clinical applications.
• Antibodies face challenges including high costs, complex development, production, and storage requirements.

Purpose of the Study:

• To engineer synthetic polymer nanoparticles (NPs) that replicate the functions of protein affinity reagents.
• To evaluate the efficacy of these NPs as abiotic alternatives to antibodies for targeting specific proteins.

Main Methods:

• Development of polymer nanoparticles with high affinity (nanomolar range) for vascular endothelial growth factor (VEGF₁₆₅).
• In vitro assays to assess the inhibition of VEGF₁₆₅ binding to its receptor VEGFR-2 and subsequent downstream signaling.
• In vivo studies using Matrigel plugs to evaluate the anti-angiogenic effects of the NPs.

Main Results:

• Engineered NPs demonstrated nM affinity for VEGF₁₆₅, effectively blocking its receptor binding and downstream signaling.
• NPs inhibited VEGF₁₆₅-dependent endothelial cell migration and invasion in vitro.
• In vivo experiments showed that NPs suppressed VEGF-mediated new blood vessel formation.

Conclusions:

• Synthetic polymer nanoparticles can be engineered to perform functions of protein affinity reagents, presenting a novel abiotic alternative.
• These NPs offer a potentially more accessible and stable option compared to traditional protein-based reagents.
• The findings suggest a new paradigm for developing affinity reagents using synthetic materials.